FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated September 26, 2013
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrant’s Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: September 26, 2013
|
|
GENETIC TECHNOLOGIES LIMITED | ||
|
|
| ||
|
|
| ||
|
|
By: |
/s/ Thomas Howitt | |
|
|
|
Name: |
Thomas Howitt |
|
|
|
Title: |
Chief Financial Officer |
Exhibit 99.1
ASX ANNOUNCEMENT
26 September 2013
ImmunAid Limited commences second round fundraising program
Melbourne, Australia; 26 September 2013: As foreshadowed in its ASX announcement dated 10 July 2013, Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to report that ImmunAid Limited (“ImmunAid”), in which GTG holds 4,500,000 shares representing a 45% equity interest and is currently the largest shareholder, has commenced its second round of fundraising, with the first funds in this new round now having been received by ImmunAid.
Such new funds are being raised by ImmunAid via the issue of ordinary shares in ImmunAid to arm’s-length investors at an issue price of $5.00 per share. This compares favourably with the issue price at which ImmunAid issued shares in its round one fundraising in April 2012 of $1.00 per share. While the funds received to date are modest, negotiations are continuing with a number of potential investors in Australia, USA and Europe to raise significant additional funds for ImmunAid as part of its round two fundraising.
ImmunAid intends to use the proceeds of this latest fundraising to expand its global patent portfolio and to support further human and animal trials directed at validating additional applications of its breakthrough strategy for treating patients with life-threatening diseases, such as cancer and auto-immune disease.
FOR FURTHER INFORMATION PLEASE CONTACT
Dr. Mervyn Jacobson
Chief Executive Officer
ImmunAid Limited
Phone: +61 3 9553 8603
About Genetic Technologies Limited
Genetic Technologies was an early pioneer in recognizing important new applications for “non-coding” DNA (Deoxyribonucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species. Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio. Genetic Technologies is a company listed on both the ASX and NASDAQ with operations in the USA and Australia. For more information, please visit www.gtglabs.com.